Clorox shares took a sharp hit on Friday, falling 6.4% to close at $90.02, after the company announced that Chair and CEO Linda Rendle would be stepping down for health reasons. The news added a layer of succession risk to a stock already grappling with sluggish sales growth and a reduced profit forecast.
The decline marked a significant underperformance relative to the broader market. The S&P 500 edged up 0.2%, while the Dow Jones Industrial Average gained 0.7% and the Nasdaq Composite rose 0.2%, buoyed by technology stocks. Trading volume surged to 4.6 million shares, well above average, as investors reacted to the leadership change.
Rendle, a 23-year veteran of the Oakland, California-based company, said she is now cancer-free after being diagnosed with early-stage breast cancer. She noted that ongoing treatment to prevent a recurrence has led her to reconsider her health and family priorities. In a personal note, she emphasized that nothing would change in the short term and that she remains focused on strategy, execution, and the transition until a successor is named. The company has formed an independent board committee and retained an executive search firm to handle the process.
The CEO departure compounds existing headwinds for Clorox. The company reported flat net sales of $1.67 billion for its fiscal third quarter, with gross margin slipping to 43.2% from 44.6% a year ago. For fiscal 2026, Clorox now expects net sales to fall 6% and adjusted earnings per share in the range of $5.45 to $5.65, below its previous guidance.
Analysts have taken a cautious stance. Goldman Sachs analyst Bonnie Herzog lowered her price target on Clorox to $83 from $94, maintaining a Sell rating. She cited the company's weak guidance, ongoing cost issues, the integration of GOJO Purell, and the transition to a new ERP back-office system as key concerns. However, not all analysts are bearish. Morningstar analyst Erin Lash described the shares as "a bargain" in a note dated May 28, suggesting that some investors may view the selloff as a buying opportunity.
Clorox's peers in the consumer staples sector also faced pressure. Procter & Gamble fell 1.6%, Kimberly-Clark lost 2.6%, and Colgate-Palmolive slipped 1.7%. The Consumer Staples Select Sector SPDR Fund, which tracks a broad group of these stocks, declined 1.8%.
Investors will be watching closely next week when Rendle and CFO Luc Bellet are scheduled to speak at the dbAccess Global Consumer Conference in Paris on Wednesday, June 3, at 6 a.m. ET. The market will be looking for updates on the CEO search, the GOJO integration, gross margin trends, and whether the company intends to stick with its revised fiscal 2026 targets.
The risk of a prolonged CEO search or a rougher-than-expected reset under a new leader could keep the stock under pressure. A smooth transition, a pickup in retail demand, and effective cost-cutting could help stabilize the shares. However, another guidance cut, market share losses, or a slower-than-expected GOJO deal might push Clorox to the lower end of its 52-week range.
